{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-07T00:16:13.081432+00:00","company":{"ticker":"VMD","cik":1729149,"company_name":"VIEMED HEALTHCARE, INC."},"pagination":{"limit":100,"returned":8,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"shareholder_vote","fact_key":"cb7fb49ba2d274b3fe7a852981ad22410141a748","cik":1729149,"ticker":"VMD","company_name":"VIEMED HEALTHCARE, INC.","filed_at":"2026-06-04T20:07:58+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Advisory vote on executive compensation","proposal_type":"say_on_pay","results":[{"broker_non_votes":"5,139,308","subject":null,"votes_abstain":"132,006","votes_against":"1,388,461","votes_for":"20,863,084","votes_withheld":null}]},"claim":"VIEMED HEALTHCARE, INC. shareholders approved Advisory vote on executive compensation.","evidence_excerpt":"Shareholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers (the “say-on-pay” vote).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001729149-26-000034","anchor_url":"https://secwatch.observer/filing/0001729149-26-000034#claim-cb7fb49ba2d274b3fe7a852981ad22410141a748","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1729149/000172914926000034/0001729149-26-000034-index.htm"},{"fact_type":"shareholder_vote","fact_key":"125bff078a4c6a4e8f4e3a4df6597dfbbd87c6a8","cik":1729149,"ticker":"VMD","company_name":"VIEMED HEALTHCARE, INC.","filed_at":"2026-06-04T20:07:58+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Ratification of Second Amendment to the 2024 LTIP","proposal_type":"equity_plan","results":[{"broker_non_votes":"5,139,306","subject":null,"votes_abstain":"227,867","votes_against":"2,267,640","votes_for":"19,888,046","votes_withheld":null}]},"claim":"VIEMED HEALTHCARE, INC. shareholders approved Ratification of Second Amendment to the 2024 LTIP.","evidence_excerpt":"Shareholders approved an ordinary resolution to ratify, confirm, and approve the Second Amendment to the 2024 LTIP.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001729149-26-000034","anchor_url":"https://secwatch.observer/filing/0001729149-26-000034#claim-125bff078a4c6a4e8f4e3a4df6597dfbbd87c6a8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1729149/000172914926000034/0001729149-26-000034-index.htm"},{"fact_type":"shareholder_vote","fact_key":"dac2ff0f18ee25d1d7c21b1808f1c79736c27032","cik":1729149,"ticker":"VMD","company_name":"VIEMED HEALTHCARE, INC.","filed_at":"2026-06-04T20:07:58+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-12-31","outcome":"passed","proposal_text":"Appointment of Ernst & Young LLP as independent auditors","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"—","subject":null,"votes_abstain":null,"votes_against":"662,778","votes_for":"26,860,081","votes_withheld":null}]},"claim":"VIEMED HEALTHCARE, INC. shareholders approved Appointment of Ernst & Young LLP as independent auditors at the 2026-12-31 meeting.","evidence_excerpt":"Shareholders approved the appointment of Ernst & Young LLP as the Company’s independent auditors for the fiscal year ending December 31, 2026, and authorized the Company's Board of Directors to fix their remuneration.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001729149-26-000034","anchor_url":"https://secwatch.observer/filing/0001729149-26-000034#claim-dac2ff0f18ee25d1d7c21b1808f1c79736c27032","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1729149/000172914926000034/0001729149-26-000034-index.htm"},{"fact_type":"shareholder_vote","fact_key":"90096d1bbb1ebe43f71664f19ec8b61ed9b9511e","cik":1729149,"ticker":"VMD","company_name":"VIEMED HEALTHCARE, INC.","filed_at":"2026-06-04T20:07:58+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Election of seven director nominees","proposal_type":"director_election","results":[{"broker_non_votes":null,"subject":"Casey Hoyt","votes_abstain":null,"votes_against":null,"votes_for":"21,367,697","votes_withheld":"1,015,859"},{"broker_non_votes":null,"subject":"W. Todd Zehnder","votes_abstain":null,"votes_against":null,"votes_for":"21,230,691","votes_withheld":"1,152,865"},{"broker_non_votes":null,"subject":"William Frazier","votes_abstain":null,"votes_against":null,"votes_for":"20,879,343","votes_withheld":"1,504,213"},{"broker_non_votes":null,"subject":"Randy Dobbs","votes_abstain":null,"votes_against":null,"votes_for":"21,861,662","votes_withheld":"521,894"},{"broker_non_votes":null,"subject":"Nitin Kaushal","votes_abstain":null,"votes_against":null,"votes_for":"21,189,191","votes_withheld":"1,194,365"},{"broker_non_votes":null,"subject":"Timothy Smokoff","votes_abstain":null,"votes_against":null,"votes_for":"21,163,913","votes_withheld":"1,219,643"},{"broker_non_votes":null,"subject":"Sabrina Heltz","votes_abstain":null,"votes_against":null,"votes_for":"17,853,293","votes_withheld":"4,530,263"}]},"claim":"VIEMED HEALTHCARE, INC. shareholders approved Election of seven director nominees.","evidence_excerpt":"Shareholders elected each of the seven director nominees to serve until the next annual meeting of shareholders or until their successors are duly elected or appointed.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001729149-26-000034","anchor_url":"https://secwatch.observer/filing/0001729149-26-000034#claim-90096d1bbb1ebe43f71664f19ec8b61ed9b9511e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1729149/000172914926000034/0001729149-26-000034-index.htm"},{"fact_type":"earnings_release","fact_key":"339a064886f70448d239c552b169cc2c70623d14","cik":1729149,"ticker":"VMD","company_name":"VIEMED HEALTHCARE, INC.","filed_at":"2026-05-05T23:59:59+00:00","payload":{"eps_text":"$0.06 per diluted share","guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":"$2.6 million","period_text":"the three months ended March 31, 2026","report_date":"2026-05-05","result_type":"reported_results","revenue_text":"$75.4 million"},"claim":"VIEMED HEALTHCARE, INC. reported the three months ended March 31, 2026 results: revenue $75.4 million, net income $2.6 million, EPS $0.06 per diluted share. Guidance raised.","evidence_excerpt":"and updated guidance for the full year ending December 31, 2026. Operational highlights (all dollar amounts are USD): • Net revenues for the quarter ended March 31, 2026 were $75.4 million, representing an increase of $16.3 million, or 28%, over net revenues reported for the comparable quarter ended March 31, 2025. • Net income attributable to Viemed for the","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001729149-26-000028","anchor_url":"https://secwatch.observer/filing/0001729149-26-000028#claim-339a064886f70448d239c552b169cc2c70623d14","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1729149/000172914926000028/0001729149-26-000028-index.htm"},{"fact_type":"executive_change","fact_key":"907f94fece","cik":1729149,"ticker":"VMD","company_name":"VIEMED HEALTHCARE, INC.","filed_at":"2025-04-14T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2025-04-14","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Bruce Greenstein resigned as Director at VIEMED HEALTHCARE, INC..","evidence_excerpt":"On April 14, 2025, Bruce Greenstein notified Viemed Healthcare, Inc. (the “Company”) of his decision to resign from the Company’s Board of Directors, effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001729149-25-000067","anchor_url":"https://secwatch.observer/filing/0001729149-25-000067#claim-907f94fece","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1729149/000172914925000067/0001729149-25-000067-index.htm"},{"fact_type":"earnings_release","fact_key":"109d4f949e02ae0bb70bd7cf3d98a0bebae036a3","cik":1729149,"ticker":"VMD","company_name":"VIEMED HEALTHCARE, INC.","filed_at":"2024-05-06T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$1.6 million","period_text":"three months ended March 31, 2024","report_date":"2024-05-06","result_type":"reported_results","revenue_text":"$50.6 million"},"claim":"VIEMED HEALTHCARE, INC. reported three months ended March 31, 2024 results: revenue $50.6 million, net income $1.6 million.","evidence_excerpt":"Net revenues for the quarter ended March 31, 2024 were $50.6 million , representing an increase of $11.0 million , or 28% , over net revenues reported for the comparable quarter ended March 31, 2023. • Net income for the quarter ended March 31, 2024 totaled $1.6 million.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001729149-24-000101","anchor_url":"https://secwatch.observer/filing/0001729149-24-000101#claim-109d4f949e02ae0bb70bd7cf3d98a0bebae036a3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1729149/000172914924000101/0001729149-24-000101-index.htm"},{"fact_type":"earnings_release","fact_key":"2b87d4b93b6cbe45b1e19596da72ec5b3a431247","cik":1729149,"ticker":"VMD","company_name":"VIEMED HEALTHCARE, INC.","filed_at":"2024-03-06T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$3.5 million","period_text":"the three months and year ended December 31, 2023","report_date":"2024-03-06","result_type":"reported_results","revenue_text":"$50.7 million"},"claim":"VIEMED HEALTHCARE, INC. reported the three months and year ended December 31, 2023 results: revenue $50.7 million, net income $3.5 million.","evidence_excerpt":"and year ended December 31, 2023. Operational highlights (all dollar amounts are USD): • Net revenues for the quarter ended December 31, 2023 reached a new Company record of $50.7 million representing an increase of $13.2 million, or 35%, over net revenues reported for the comparable quarter ended December 31, 2022. Total net revenues for the year ended December","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001729149-24-000075","anchor_url":"https://secwatch.observer/filing/0001729149-24-000075#claim-2b87d4b93b6cbe45b1e19596da72ec5b3a431247","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1729149/000172914924000075/0001729149-24-000075-index.htm"}]}